The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus
Drzewoski J. The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review. 2008:254-259.
APA
Drzewoski, J. (2008). The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, 254-259.
Chicago
Drzewoski, Józef. 2008. "The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus". Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review: 254-259.
Harvard
Drzewoski, J. (2008). The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, pp.254-259.
MLA
Drzewoski, Józef. "The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus." Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, 2008, pp. 254-259.
Vancouver
Drzewoski J. The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review. 2008:254-259.
The article describes the results of the hypoglycaemic arm of the ADVANCE Trial and compares the obtained data with the results of the ACCORD and VADT studies.
Keywords
ADVANCE, type 2 diabetes mellitus, intensive treatment, conventional treatment